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are associated with an increased risk of ischemic heart disease. The
concurrence of RLP-C measurement by different separation methods
is not well-described. This analysis assessed RLP-C by 3 commonly
used measurements including immunoseparation (IM [ApoA-I and
ApoB-100 monoclonal antibodies]), vertical auto proﬁle (VAP
[IDLþVLDL3]) and Calculated RLP-C (Total cholesterol minus HDL-C
minus LDL-C) methods using samples from a previously reported
randomized, clinical trial.
METHODS This analysis assessed fasting RLP-C in hyperlipidemic
patients (n¼2,382) treated with ezetimibe/simvastatin (E/S)10/20
mg, E/S þ niacin (N) 2g and N 2g during 24 weeks, and E/S 10/20
mg and E/S þ N 2g during 64 weeks. RLP-C levels, change from
baseline and % change from baseline were evaluated by the IM,
VAP, and Calculated methods. The relationships and agreement
among the 3 methods used in the measurement of these parameters
were assessed by Pearson correlation coefﬁcients and Bland-Altman,
respectively.
RESULTS Cholesterol mass at baseline measured by the VAP and
Calculated methods was w3-4X higher than by IM; all declined with
treatment by 24 weeks with little further reduction at 64 weeks (see
table). RLP-C change and % reduction from baseline were larger when
measured by VAP versus Calculated and IM methods. Although the 3
methods were moderately to strongly correlated (r¼0.37-0.79) for
RLP-C levels and changes, Bland-Altman plots showed little agree-
ment between the methods for RLP-C levels but slightly better
agreement for RLP-C changes (not shown).
CONCLUSIONS RLP-C deﬁned by IM, VAP and Calculated methods
differs in mass and response to pharmacologic intervention. Given the
relationship between RLP-C and IHD risk, standardization of methods
is needed for RLP-C use in risk assessment.GW26-e2366
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OBJECTIVES Changes in carotid plaque lipid-rich necrotic core
(LRNC) as assessed by magnetic resonance imaging (MRI) were
investigated in subjects who continued and discontinued statin
therapy for 2 years after a prospective study.
METHODS The Rosuvastatin Evaluation of Atherosclerotic Chinese
Patients (REACH) study in 32 lipid treatment naïve subjects with
LRNC showed a signiﬁcant reduction in LRNC during 24 months (M) of
rosuvastatin therapy. All subjects received a clinical follow-up (F/U)
visit and a repeat carotid MRI scan at 48 M as planned REACH-F/U.
Despite receiving a strong recommendation to continue the statin
therapy at 24 M when REACH was completed, only 15 subjects
continued taking statins (rosuva.¼9, simva.¼4 and atorva.¼2) in
REACH-F/U and 17 discontinued. Lipids and LRNC, both in volume (V)
and % (LRNC-V/Wall V100%), were compared between the statin-
continued and -discontinued groups at 48 M.
RESULTS There were no signiﬁcant differences in demographic,
clinical characteristics, lipids and plaque changes during 24 M in
REACH between the statin-continued and -discontinued groups in
REACH-F/U. Not surprisingly, at 48 M, Total-Cholesterol (C), LDL-C
and triglycerides were signiﬁcantly lower in subjects who continued
statin than those discontinued (16343 vs. 20730 mg/dl, p¼0.002),
(9336 vs. 13122 mg/dl, p¼0.001) and (8527 vs. 14365 mg/dl,
p¼0.003), while HDL-C levels were similar. LRNC-V and %LRNC
decreased signiﬁcantly from 24 M in the statin-continued group
(10176 mm3 at 24 M vs. 7665 mm3 at 48 M, p¼0.001) and
(17.311.9% at 24 M vs. 12.67.6% at 48 M, p¼0.04). By contrast,
subjects who discontinued statin showed non-statistically signiﬁ-
cant increase in LRNC-V and %LRNC (10393 mm3 at 24 M vs.
112106 mm3 at 48 M, p¼0.4) and (15.411.3% at 24 Mvs.
16.711.4% at 48 M, p¼0.07). Furthermore, the changes in LRNC-V
and %LRNC from 24 to 48 M were signiﬁcantly different between
the statin-continued and -discontinued groups in REACH-F/U
(-2518 vs. 914 mm3, p<0.001) and (-4.6 8.2% vs. 1.32.8%,
p¼0.009).
CONCLUSIONS Continued statin therapy leads to continued decrease
in LRNC, which indicates improved plaque stability. The REACH-F/U
results provided vascular biological evidence to strongly support long-
term statin therapy.GW26-e3950
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OBJECTIVES The oral direct thrombin inhibitor dabigatran has a pre-
dictable anticoagulant effect and may be an alternative medication to
warfarin for non-valvular atrial ﬁbrillation (AF) patients with intracardiac
thrombus. The objective is to compare the dabigatran, administered at a
ﬁxed dose of 150 mg twice daily (bid) with dose-adjusted warfarin (with a
target international normalized ratio INR level of 2.0 to 3.0).
METHODS In the trial, 41 patients who had intracardiac thrombus
detected by transesophageal echocardiography (TEE) were enrolled.
Among them, 19 patients received dabigatran 150 mg bid and the
remaining 22 patients received warfarin based on the patients’ indi-
vidual choice. Repeated TEE was performed at 3 months. The patients
was assessed after 1 month and then 3 months in the clinic; meanwhile
they were requested to contact the investigator immediately if symp-
toms developed that were suggestive of stroke, thromboembolism or
major bleeding. All statistical analyses were conducted with SPSS Sta-
tistics version 17.0 software. The thrombus dissolution ability, repre-
sented by the ratio of decreased thrombus area to original area, was
compared by Wilcoxon W test between the 2 groups. Difference with p
value < 0.05 (2-sided) was considered statistically signiﬁcant.
RESULTS Mean age of the study population was 57.77.4 years, with
36 (87.8%) male and 17 (41.5%) patients who had persistent AF, with
no differences between the 2 groups. Thrombus area ranges from 0.1
to 4.48 cm2 and the locations of thrombi were mainly in left atrial
appendage (LAA). The thrombus area in warfarin group were larger
than in dabigatran group (1.451.04 vs. 0.640.54, p < 0.05). Mean
number of INR examination values obtained in the warfarin group was
10 during the therapy course. Time in therapeutic range of INR (TTR)
was above 60%. Complete thrombus resolution was documented by
repeated TEE in 17 patients in dabigatran group (17 of 19) and 17 pa-
tients in warfarin group (17 of 22). The ability of thrombus dissolution,
represented by the ratio of decreased thrombus area to original area,
was similar between the 2 groups (p > 0.05). Any bleeding, occurred in
7 patients receiving dabigatran and in 8 patients receiving warfarin.
No major or fatal bleeding occurred in both two groups. One patient in
the warfarin group experienced ischemic stroke. Four patients in the
dabigatran group had gastrointestinal discomfort. Only one patient
discontinued dabigatran for about two weeks and needed drug
intervention, and after 3-month anticoagulation, a secondary TEE
detected an increased thrombus.
CONCLUSIONS Dabigatran has similar effect compared with warfarin
for the treatment of intracardiac thrombus in patients with non-
valvular AF. Uninterrupted dabigatran is particularly essential and
crucial for ﬁbrinolysis and drug discontinuance would affect
thrombus dissolution effect. It should be noticed that dabigatran lead
to gastrointestinal discomfort event.
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OBJECTIVES To compare the inhibitory effect of ticagrelor and clo-
pidogrel on the platelet of patients with acute coronary syndro-
me(ACS) after percutaneous coronary artery intervention(PCI).
METHODS 255 cases of patients with ACS admitted in our hospital
from March 2014 to August 2014 were selected for this study, in which
85 cases were treated by ticagrelor and aspirin and the other 170 cases
were treated by clopidogrel and aspirin respectively. All the patients
were given PCI treatment, and the thrombelastography(TEG) were
detected 2 days after PCI and oral administration of load dosage of
antiplatelet drugs, the platelet inhibition ratio through ADP and AA
pathway were observed and compared between two groups.
RESULTS Adenosine diphosphate(ADP)-induced platelet inhibition
ratio in clopidogrel group was signiﬁcantly lower than that of in
ticagrelor group (66.6025.57% vs 82.1018.87%, P<0.05). Arach-
idonic acid(AA)-induced platelet inhibition ratio in clopidgrel was
similar to that of in ticagrelor group (88.7023.89% vs 90.3218.09%,
P>0.05). There were signiﬁcant differences between clopidogrel
